PMID- 34096755
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1936-2293 (Electronic)
IS  - 1064-1297 (Linking)
VI  - 29
IP  - 5
DP  - 2021 Oct
TI  - Ethnoracial health disparities and the ethnopsychopharmacology of 
      psychedelic-assisted psychotherapies.
PG  - 539-554
LID - 10.1037/pha0000490 [doi]
AB  - Emerging evidence from randomized, double-blind, placebo-controlled clinical 
      trials suggests psychedelic compounds such as 3,4-methylenedioxymethamphetamine 
      (MDMA), psilocybin, and lysergic acid diethylamide (LSD), when administered as an 
      adjunct to psychotherapy, that is, psychedelic-assisted psychotherapy (PAP), may 
      be beneficial for treating substance use disorders, posttraumatic stress disorder 
      (PTSD), depression, anxiety, and other psychiatric conditions. Previous 
      ethnopsychopharmacological research has identified ethnoracial differences in the 
      metabolism, safety, and efficacy of psychotropic drugs, yet no studies have 
      directly investigated the impact of ethnoracially based differences in 
      psychedelic drug pharmacology. Although there is an extensive global history of 
      psychedelic use among peoples of various cultures, ethnicities, and 
      intersectional identities, psychedelic research has been conducted almost 
      exclusively on White populations in North America and Western Europe. The failure 
      to include Black, Indigenous, and People of Color (BIPOC) in psychedelic research 
      trials neglects the ethnic, racial, and cultural factors that may impact 
      individual responses to PAP and thereby prevents generalizability of findings. 
      This article investigates the impact of biological and social factors related to 
      culture, ethnicity, and race on pharmacological responses to PAP, as well as 
      clinical outcomes. The limitations of ethnopsychopharmacology are discussed, and 
      the authors present expected cultural, clinical, and public health benefits of 
      expanding funding for this area. This work will draw attention to the unique and 
      individualized needs of ethnoracially diverse clients in therapeutic settings and 
      is intended to inform future PAP trials. (PsycInfo Database Record (c) 2021 APA, 
      all rights reserved).
FAU - Fogg, Colleen
AU  - Fogg C
AD  - Yale-New Haven Health.
FAU - Michaels, Timothy I
AU  - Michaels TI
AUID- ORCID: 0000-0002-3048-6860
AD  - The Zucker Hillside Hospital.
FAU - de la Salle, Sara
AU  - de la Salle S
AD  - Faculty of Social Sciences.
FAU - Jahn, Zoe W
AU  - Jahn ZW
AD  - Department of Physiology and Neurobiology.
FAU - Williams, Monnica T
AU  - Williams MT
AD  - Faculty of Social Sciences.
LA  - eng
GR  - Canada Research Chairs Program/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20210607
PL  - United States
TA  - Exp Clin Psychopharmacol
JT  - Experimental and clinical psychopharmacology
JID - 9419066
RN  - 0 (Hallucinogens)
RN  - 2RV7212BP0 (Psilocybin)
RN  - 8NA5SWF92O (Lysergic Acid Diethylamide)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - *Hallucinogens
MH  - Humans
MH  - Lysergic Acid Diethylamide
MH  - *N-Methyl-3,4-methylenedioxyamphetamine
MH  - Psilocybin
MH  - Psychotherapy
EDAT- 2021/06/08 06:00
MHDA- 2021/11/26 06:00
CRDT- 2021/06/07 12:14
PHST- 2021/06/08 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
PHST- 2021/06/07 12:14 [entrez]
AID - 2021-53471-001 [pii]
AID - 10.1037/pha0000490 [doi]
PST - ppublish
SO  - Exp Clin Psychopharmacol. 2021 Oct;29(5):539-554. doi: 10.1037/pha0000490. Epub 
      2021 Jun 7.